Key Stats for Thermo Fisher Stock
- 52-Week Range: $385 to $644
- Current Price: $442
- Street Mean Target: $612
- Street High Target: $750
- Analyst Consensus: 19 Buys / 5 Outperforms / 3 Holds / 2 No Opinions
- TIKR Model Target (Dec. 2030): $691
Thermo Fisher Stock Beats Q1 Estimates but Warns Academic Demand Won’t Recover in 2026
Thermo Fisher Scientific (TMO) delivered a Q1 2026 earnings beat that would normally send a stock higher, but the life-science tools giant fell sharply on April 23 after management confirmed academic and government demand would remain suppressed through year-end.
Revenue rose 6% to $11.01 billion, clearing the consensus estimate of $10.85 billion, and adjusted EPS of $5.44 beat the Street’s $5.24 estimate by $0.20.
The headline beat masked a more complex picture: organic revenue growth came in at just 1%, weighed down by one fewer selling day in the quarter and deliberate revenue phasing in the pharma services business, which delivers a much heavier back-half contribution.
CEO Marc Casper stated on the Q1 2026 earnings call that “our assumption is that for the year, we would see greater stability and the U.S. end market improving modestly over time, but not back to normal,” drawing a direct line between federal funding cuts and the sustained pressure on Thermo Fisher’s instruments segment.
The Clario acquisition, closed March 24 for $8.88 billion in cash, added $30 million of revenue and $0.01 of adjusted EPS to Q1 and materially expanded Thermo Fisher’s clinical research capabilities by embedding endpoint data solutions directly into pharma and biotech trial workflows.
Thermo Fisher raised full-year revenue guidance to a range of $47.3 billion to $48.1 billion and lifted adjusted EPS guidance to $24.64 to $25.12, representing 8% to 10% earnings growth over 2025, crediting both the Clario addition and strong first-quarter operational performance.
The company also flagged a new inflation risk tied to the Middle East conflict, with CFO Jim Meyer noting that oil price volatility required a forward placeholder in guidance, even as management expressed confidence in its ability to offset the pressure through PPI Business System productivity initiatives.
TMO Stock Holds 24 Buy-Side Ratings Despite a Below-Normal Tools Recovery Timeline
The Street’s bull thesis on Thermo Fisher stock centers on a recovery the data has not yet confirmed at scale, and 24 analysts with buy-side ratings are betting the setup is durable enough to wait.
The consensus view entering this quarter was that pharma and biotech demand would stabilize first, with academic and government recovering later in 2026. Q1 validated the pharma leg but offered little on the academic side, and management’s explicit “not back to normal” framing pushed the recovery horizon into 2027 for that segment.
The metric that most directly tests the thesis is EBITDA: consensus projects Q2 2026 EBITDA of around $2.90 billion, up around 10% year over year, accelerating sharply from Q1’s 6.2% growth as the Clario contribution scales and pharma services revenue phasing normalizes in the back half.
Looking further out, consensus estimates EBITDA reaching around $3.61 billion by Q4 2026, a roughly 14% year-over-year gain, reflecting conviction that Thermo Fisher’s bioproduction business, clinical research momentum, and NVIDIA collaboration will sustain earnings velocity even without a full academic recovery.
The analyst count is 19 Buys, 5 Outperforms, and 3 Holds, with a mean price target of around $612 and a median of $615, implying around 38% upside from the current price of $442. The spread between the Street high of $750 and the low of $490 reflects genuine uncertainty about recovery timing rather than a debate about business model quality.
JPMorgan’s “overweight” framing captures the mainstream view: Thermo Fisher stock is well-positioned to gain share during the recovery, but the end-market improvement is progressing more gradually than initially hoped. The holds cluster is not a bearish view on the company; it is a patience call on timing.
RBC resumed coverage on May 15 with a “sector perform” rating and a $490 price target, the most cautious recent signal from a major firm, citing a view that the recovery trajectory does not yet justify the re-rating embedded in higher targets.
TIKR’s Model Prices Thermo Fisher at $691 as Bioproduction and Clario Drive the Compound
TIKR’s base case values Thermo Fisher Scientific at around $691 per share, anchored to a mid-case revenue CAGR of around 5% from 2025 through 2035 and a net income margin expansion to around 21%, driven by bioproduction scale, Clario integration, and NVIDIA collaboration workflows materializing commercially.
At $442 against a mid-case target of around $691, Thermo Fisher stock is undervalued, with TIKR’s model implying around 56% total return over the next 4 and a half years at an annualized IRR of around 10%.
TIKR’s scenario framework frames the investment around two variables: how quickly the instruments segment normalizes as academic funding stabilizes, and whether the Clario acquisition delivers its earn-out milestones tied to 2026 and 2027 performance (up to $400 million).
Base Case:
- Revenue CAGR of around 5% through 2035 supports TIKR’s mid-case stock price of around $943 by December 2034, representing around 113% total return
- Bioproduction reshoring tailwind builds through 2027 and 2028 as domestic drug manufacturing contracts already signed begin generating revenue
- Clario’s endpoint data platform scales into Thermo Fisher’s existing biopharma customer base, extending the accelerated drug development offering that drove strong authorizations growth in Q1
- NVIDIA collaboration produces commercial instrument and workflow solutions by 2027, expanding addressable revenue in autonomous laboratory infrastructure
Downside Risk:
- Middle East conflict-driven inflation exceeds management’s internal mitigation capacity, compressing adjusted operating margins below the 70 basis points of expansion guided for full-year 2026
- Clario earn-out milestones are not achieved in 2026 or 2027, reducing the effective return profile of the $8.88 billion acquisition and adding execution risk to near-term guidance
Is Thermo Fisher Scientific stock undervalued?
TIKR’s mid-case model values TMO at around $691 per share, implying around 56% upside from the current price of $442. With 24 analysts issuing Buy or Outperform ratings and a Wall Street mean target of around $612, institutional consensus points to a significant discount to intrinsic value.
The key variable is instruments segment recovery: if U.S. and China academic funding normalizes in 2027, the base case holds.
How did Thermo Fisher perform in Q1 2026 earnings?
Thermo Fisher reported Q1 2026 adjusted EPS of $5.44, beating the consensus estimate of $5.24 by $0.20, and revenue of $11.01 billion, above the $10.85 billion estimate.
Organic growth came in at 1%, held back by one fewer selling day and pharma services revenue phasing.
The company raised full-year adjusted EPS guidance to $24.64 to $25.12 and revenue guidance to $47.3 billion to $48.1 billion.
Should You Invest in Thermo Fisher Scientific Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher Scientific Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher Scientific Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze TMO stock on TIKR for Free →
